Rethinking the Resilient Brain: The New Frontier of Immuno-Neurology
Maxwell Biosciences is part of a scientific revolution that sees a different story in the data. We believe that many of the most devastating brain diseases are not just failures of aging, but the result of a failed immune conversation. The brain is a fortress, but even the strongest walls need a modern defense.
Fighting Neonatal Sepsis in India
Neonatal sepsis is a severe blood infection in newborns and is the leading cause of infant mortality in India. Over 50% of these cases are now multi-drug resistant (MDR). Traditional antibiotics, once our strongest defense, are increasingly failing against "superbugs," leaving doctors and parents with few options.
Maxwell Biosciences Subsidiary Havih Announces Partnership with the Government of Andhra Pradesh
Havih Envirosciences, a subsidiary of Maxwell Biosciences, announces a strategic partnership with the Government of Andhra Pradesh to establish advanced pharmaceutical research and production capabilities, supporting branded innovation, India-based IP creation and high-skill job growth.
Havih, a Maxwell Biosciences Subsidiary, Announces Partnership with the Government of Andhra Pradesh
Havih Envirosciences, a Maxwell Biosciences subsidiary, partners with the Government of Andhra Pradesh to build advanced pharma R&D, create India-based IP and support the shift beyond generics.
Former US Congressman Dr. Brad Wenstrup Joins Maxwell Board
Former US Congressman Dr. Brad Wenstrup joins Maxwell Biosciences Board of Directors. Dr. Wenstrup has broad experience in government, military and civilian medicine and expertise in managing bacterial, fungal and viral infections, key to Maxwell’s vision to create health for the world.
Maxwell Biosciences Marks Scientist Appreciation Day With Renewed Call to Recognize Scientists
Maxwell Biosciences marks its company holiday, Scientist Appreciation Day, with a call to recognize scientists and connect with underfunded, visionary researchers.
Maxwell Biosciences Announces Closing of $20M Financing Round
Maxwell Biosciences raises $20M to launch Claromer™ clinical trials and expand AI-driven R&D, targeting infectious disease without harming the microbiome.
Maxwell Biosciences Announces AI Department & Hiring of Jon McClure
Maxwell Biosciences, a global health technology company pioneering immune-inspired small molecules called Claromers™, today announced new engineering leadership for its Artificial Intelligence efforts—further cementing its decade-long commitment to AI-first innovation.
Maxwell Targets $500B Cosmetics Market with Microbiome-Friendly Antiseptics
Maxwell Biosciences announces its entry into the global cosmetics market through strategic partnerships and licensing deals. Its Claromer™ technology—engineered to support the skin microbiome—is now being tested by leading skincare companies seeking next-generation, immune-inspired solutions.
Maxwell Biosciences Secures Anti-Diarrheal US Military Agreement
Maxwell Biosciences announces our 7th cooperative agreement with the US military to test Claromers™ for the treatment and prevention of diarrheal disease.
Combating Infectious Diseases: Maxwell Biosciences Partners with U.S. Military
Discover how Maxwell Biosciences is advancing biodefense with its Claromer™ platform in an exclusive Contract Pharma interview. CEO Joshua McClure discusses U.S. Military partnerships, a $3M MTEC award and innovative therapeutics for infectious diseases like Dengue Fever.
Maxwell Biosciences Announces Appointment of José Antonio Alas to Its Board of Directors
Appointment of José Antonio Alas brings more than 30 years of biotech expertise, including global business development, international partnerships, patient access to innovative medications and product launches as the company advances its Claromer™ drug discovery platform
Maxwell Biosciences Selected to Receive a Nearly $3M Award from Medical Technology Enterprise Consortium (MTEC)
Austin, Texas--(Newsfile Corp. - October 24, 2024) - Maxwell Biosciences is developing a new type of anti-infective drug designed to improve upon natural immune system peptides. The company announced today it has been selected to receive a nearly $3M award from the Medical Technology Enterprise Consortium (MTEC). MTEC works in cooperation with the U.S. Army Medical Research and Development Command (USAMRDC) and the U.S. Department of Defense.
